Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vigeo Therapeutics
Cambridge, Massachusetts, United States
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
VT1021 demonstrated single-agent efficacy in rGBM with a 50% disease control rate (22 subjects: 3 complete response, 1 partial response, 7 stable disease)[2][4][8]. Notably, one patient remained tumor-free for over 3 years. The agent is progressing in an adaptive Phase 2/3 registration study (GBM AGILE)[2][4].
- Therapeutic areas
- GastroenterologyOncologyImmunologyNeurology
- Modalities
- PeptidesSmall moleculeBiologic
- Industry
- Biotech
02
Partnerships
Global Coalition for Adaptive Research (GCAR)Morningside Venture Investments (investor/strategic)
Beyond the preview
Go deeper on Vigeo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vigeo Therapeutics.